Aliskiren
Spécifications
173334-57-1Numéro CAS
605-672-4Numéro CE
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamideNom IUPAC
C30H53N3O6Formule chimique
551.8 g/molMasse molaire
Aliskiren; 173334-57-1; SPP100; SPP 100; aliskirene; Aliskireno; SPP-100; CGP 60536; 502FWN4Q32; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; CHEBI:601027; DTXSID40891494; CGP-060536B; CGP-60536; aliskirenum; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-((4-methoxy-3-(3-methoxypropoxy)phenyl)methyl)-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamide; RefChem:56248; C09XA02; CGP060536B; DTXCID401030595; CGP60536; Aliskiren(CGP 60536); MFCD09839018; CHEMBL1639; CGP60536B; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; Aliskiren [INN]; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C30H53N3O6; NCGC00186464-01; CGP 60536;CGP60536B;SPP 100; Aliskiren [USAN:INN:BAN]; UNII-502FWN4Q32; Aliskiren?; HSDB 7843; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; Rasilez (TN); Aliskiren (Standard); Aliskiren-hemifumarate; ALISKIREN [MI]; Aliskiren (USAN/INN); ALISKIREN [HSDB]; ALISKIREN [USAN]; ALISKIREN [VANDF]; ALISKIREN [WHO-DD]; ALISKIREN [EMA EPAR]; SCHEMBL455490; GTPL4812; orb1704862; SCHEMBL29521564; BDBM17950; UXOWGYHJODZGMF-QORCZRPOSA-N; GLXC-05705; ALBB-027274; MSK11172; EBC-27307; HY-12176R; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; NCGC00186464-02; NCGC00186464-13; AS-80517; FA134549; HY-12176; SBI-0206888.P001; NS00007787; D03208; EN300-708809; T22233; AB01274865-01; AB01274865_02; AB01274865_03; F793779; Q414904; BRD-K30020243-051-01-7; BRD-K30020243-051-02-5; BRD-K30020243-051-03-3; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; 5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide fumar ate; Benzeneoctanamide, |A-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-|A-hydroxy-4-methoxy-3-(3-methoxypropoxy)-|A,|AE-bis(1-methylethyl)-, (|AS,|AS,|AS,|AES)-; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-me thylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C41Synonymes
Produits contenant Aliskiren
RASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAliskirenAliskirenAliskiren